These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 17990284)

  • 21. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio.
    van Baal PH; Feenstra TL; Hoogenveen RT; de Wit GA; Brouwer WB
    Health Econ; 2007 Apr; 16(4):421-33. PubMed ID: 17039573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality-adjusted life years: how useful in medico economic studies.
    Brauer CA; Neumann PJ
    Fundam Clin Pharmacol; 2005 Dec; 19(6):603-7. PubMed ID: 16313271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The importance of age in allocating health care resources: does intervention-type matter?
    Johri M; Damschroder LJ; Zikmund-Fisher BJ; Ubel PA
    Health Econ; 2005 Jul; 14(7):669-78. PubMed ID: 15497189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale.
    Elbasha EH; Messonnier ML
    Health Econ; 2004 Jan; 13(1):21-35. PubMed ID: 14724891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient preferences and cost-utility analysis.
    Elnitsky CA; Stone P
    Appl Nurs Res; 2005 May; 18(2):74-6. PubMed ID: 15991103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-related quality of life after stroke: review of the literature and implications for future research.
    Tseng MC; Lin HJ
    Acta Neurol Taiwan; 2007 Mar; 16(1):7-12. PubMed ID: 17486727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of QALYS and the welfare implications of survivor consumption and leisure forgone.
    Nyman JA
    Health Econ; 2011 Jan; 20(1):56-67. PubMed ID: 19946890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new and more robust test of QALYs.
    Doctor JN; Bleichrodt H; Miyamoto J; Temkin NR; Dikmen S
    J Health Econ; 2004 Mar; 23(2):353-67. PubMed ID: 15019761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness and quality-of-life analysis of physician-staffed helicopter emergency medical services.
    Ringburg AN; Polinder S; Meulman TJ; Steyerberg EW; van Lieshout EM; Patka P; van Beeck EF; Schipper IB
    Br J Surg; 2009 Nov; 96(11):1365-70. PubMed ID: 19847879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Should IQWiG revise its methods of cost-effectiveness analysis in order to comply with more widely accepted health economical evaluation standards?].
    Lübbe W
    Dtsch Med Wochenschr; 2010 Mar; 135(12):582-5. PubMed ID: 20234995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [QALY or willingness to pay?].
    Steurer J
    Praxis (Bern 1994); 1999 Feb; 88(8):333-8. PubMed ID: 10097643
    [No Abstract]   [Full Text] [Related]  

  • 33. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC; Lade RJ; Adewoyin T; Chong NV
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
    Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses.
    Bala MV; Zarkin GA; Mauskopf JA
    Value Health; 2002; 5(4):338-46. PubMed ID: 12102696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In defence of societal sovereignty: a comment on Nyman 'the inclusion of survivor consumption in CUA'.
    Richardson JR; Olsen JA
    Health Econ; 2006 Mar; 15(3):311-3; discussion 319-22. PubMed ID: 16389655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality-adjusted life years.
    Bravo Vergel Y; Sculpher M
    Pract Neurol; 2008 Jun; 8(3):175-82. PubMed ID: 18502950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How much are Americans willing to pay for a quality-adjusted life year?
    Weinstein MC
    Med Care; 2008 Apr; 46(4):343-5. PubMed ID: 18362811
    [No Abstract]   [Full Text] [Related]  

  • 39. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
    Bolin K; Mörk AC; Willers S; Lindgren B
    Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.